InvestSMART

Tryptamine Therapeutics Limited (ASX: TYP) - Announcements

Current share price for TYP : $0.034 0.002 (5.56%)+

ASX company news and announcements for Tryptamine Therapeutics Limited (TYP) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Tryptamine Therapeutics Limited (TYP) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Tryptamine Therapeutics Limited (TYP), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Tryptamine Therapeutics Limited (TYP)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
- Positive Phase 2a fibromyalgia results across all patients 12 Aug 2024 9:30AM $0.021 $0.034 risen by 61.90%
- Trading Halt 7 Aug 2024 5:37PM $0.021 $0.034 risen by 61.90%
- Quarterly Activities Report and Appendix 4C 31 Jul 2024 8:44AM $0.020 $0.034 risen by 70%
- TechKnow Invest Roadshow presentation and livestream links 30 Jul 2024 8:52AM $0.020 $0.034 risen by 70%
- Appointment of Professor Phillipa Hay to TYPs SAB 30 Jul 2024 8:39AM $0.020 $0.034 risen by 70%
- Psychiatry professor David Castle appointed to TYPs SAB 29 Jul 2024 9:29AM $0.020 $0.034 risen by 70%
- First patient dosed in Phase 2a IBS trial at Mass General 24 Jul 2024 8:34AM $0.020 $0.034 risen by 70%
- Notification of cessation of securities - TYP 22 Jul 2024 5:43PM $0.023 $0.034 risen by 47.83%
- Phase 2a Fibromyalgia clinical study completed at U-M 10 Jul 2024 9:24AM $0.019 $0.034 risen by 83.78%
- Maiden dosing of TRP-8803 completed in global first 1 Jul 2024 10:28AM $0.021 $0.034 risen by 61.90%
- Dr Robin Carhart-Harris renews role as SAB Chair 26 Jun 2024 8:25AM $0.021 $0.034 risen by 61.90%
- Appointment product registration & reimbursement strategy 19 Jun 2024 8:24AM $0.020 $0.034 risen by 70%
- Change of Director's Interest Notice - JC 17 Jun 2024 8:27AM $0.020 $0.034 risen by 70%
- Details of Company Address 7 Jun 2024 1:30PM $0.022 $0.034 risen by 54.55%
- Change of Director's Interest Notice - JC 7 Jun 2024 8:27AM $0.021 $0.034 risen by 61.90%
- Change of Director's Interest Notice - JC 6 Jun 2024 10:07AM $0.022 $0.034 risen by 54.55%
- Change of Director's Interest Notice - JC 4 Jun 2024 8:21AM $0.024 $0.034 risen by 41.67%
- Upcoming Expiry of Options 31 May 2024 4:58PM $0.023 $0.034 risen by 47.83%
- Change of Director's Interest Notice - JC 31 May 2024 8:20AM $0.023 $0.034 risen by 47.83%
- Tryptamine Therapeutics Limited commences trading on the ASX 29 May 2024 9:41AM n/a $0.034 n/a
- Investor Presentation May 2024 Precision Psychedelic Therapy 29 May 2024 9:40AM n/a $0.034 n/a
- Reinstatement to Quotation 29 May 2024 9:27AM n/a $0.034 n/a
- Amended Anticipated Reinstatement to Official Quotation 28 May 2024 5:48PM n/a $0.034 n/a
- Pre-Quotation Disclosures 28 May 2024 4:08PM n/a $0.034 n/a
- Half Year Acc Discussion Tryp Therapeutics end 29 Feb 2024 28 May 2024 4:07PM n/a $0.034 n/a

101 - 125 of 144 results

Page 5 of 6

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.